Lakefront Biotherapeutics - American Depositary Shares (LKFT)

29.47
+0.92 (3.22%)
NASDAQ · Last Trade: Sep 21st, 2:37 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamigmarketbeat.com
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines. Speaking at M
Via MarketBeat · September 21, 2026
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launchfool.com
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
Via The Motley Fool · May 23, 2026
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%fool.com
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Via The Motley Fool · May 23, 2026